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We would like to thank Dr Braillon for his letter1 about
our study investigating the relative effectiveness of
varenicline and nicotine replacement therapy (NRT) using
electronic medical records in the Clinical Practice Research
Datalink (CPRD).2 We agree that the CPRD is an abun-
dant resource. About 12% of GP practices in England are
currently participating in CPRD Gold.3,4
National Institute for Clinical Excellence guidelines state
that combination-NRT should be prescribed to patients who
show a high level of dependence on nicotine or who have
found single forms of NRT inadequate in the past.5 In our
study, 23% of patients received more than one prescription
for NRT.2 Previous research using data from the NHS Stop
Smoking Services has found that varenicline is marginally
more effective than combination NRT at 4-week follow-
up[odds ratio, 1.08; 95% confidence interval (CI), 1.00 to
1.16].6 A Cochrane review pooled effect estimates from
seven randomized controlled trials comparing combination-
with single-NRT, and found that combination-NRT was
more effective (risk ratio, 1.35; 95% CI, 1.11 to 1.63).7
Programmes of behavioural support for people using
smoking cessation medication increase the chances of quit-
ting (risk ratio, 1.25; 95% CI, 1.08 to 1.45).8 However, an
English survey of smokers conducted between 2006 and
2012 found that only 4.8% of people attempting to quit
smoking had used both prescription pharmacotherapy and
specialist behavioural support.9 In our study, it is possible
that behavioural support was available to patients through
primary care-based stop-smoking services, which are pre-
dominantly led by practice nurses or smoking cessation
advisers. However, our data did not contain information
on whether patients accessed behavioural support. Referral
to and attendance at smoking cessation behavioural sup-
port is not routinely recorded by GPs.
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